Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
about
Functionality of disintegrants and their mixtures in enabling fast disintegration of tablets by a quality by design approachImproved Stability of a Model IgG3 by DoE-Based Evaluation of Buffer FormulationsUnderstanding pharmaceutical quality by designAccelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools.Continuous downstream processing for high value biological products: A Review.Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.Using simple models to describe the kinetics of growth, glucose consumption, and monoclonal antibody formation in naive and infliximab producer CHO cells.High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.Predicting protein-protein interactions of concentrated antibody solutions using dilute solution data and coarse-grained molecular models.A step forward towards the development of stable freeze-dried liposomes: a quality by design approach (QbD).
P2860
Q34265134-75F55F3E-1D4A-4B80-9D65-0341AB2BBBE5Q36693770-7A180FCE-0273-4CCC-8751-B3E5D12CD824Q38214058-3DB291BE-B5FF-4D3F-A51D-75EEAAEF0DC9Q38313350-C784B028-8DBA-4058-B598-0C72360CC3F5Q38543755-6E4FF23F-2E81-4CEE-A945-37773DF6E806Q40244595-FE466B69-BC9F-402D-948A-29A4D44D90BBQ42049559-777A9BDF-2269-45AA-8728-1AB20911DB42Q46977209-E7BD9653-8268-419C-958B-77C41E08875AQ47221856-B5A9DADB-A55F-4446-983B-3689CA868966Q48369535-5EDB2364-F709-4E97-8BF5-DF09A75A2BAD
P2860
Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Quality by design: impact of f ...... ophilized monoclonal antibody.
@ast
Quality by design: impact of f ...... ophilized monoclonal antibody.
@en
type
label
Quality by design: impact of f ...... ophilized monoclonal antibody.
@ast
Quality by design: impact of f ...... ophilized monoclonal antibody.
@en
prefLabel
Quality by design: impact of f ...... ophilized monoclonal antibody.
@ast
Quality by design: impact of f ...... ophilized monoclonal antibody.
@en
P2093
P1476
Quality by design: impact of f ...... ophilized monoclonal antibody.
@en
P2093
Cyrus Agarabi
David Awotwe-Otoo
Elizabeth Casey
Geoffrey K Wu
Kurt A Brorson
Mansoor A Khan
Rakhi B Shah
Scott Lute
P304
P356
10.1016/J.IJPHARM.2012.08.033
P407
P577
2012-08-25T00:00:00Z